{"id":55536,"date":"2023-04-05T13:06:35","date_gmt":"2023-04-05T11:06:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/"},"modified":"2023-04-05T13:06:35","modified_gmt":"2023-04-05T11:06:35","slug":"enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","title":{"rendered":"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)"},"content":{"rendered":"
\n

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc<\/a>. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 33rd<\/sup> European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18 both virtually and at the Bella Center Copenhagen in Copenhagen, Denmark.<\/p>\n

<\/a><\/p>\n

\nPoster Presentations:
\n
<\/span>Date<\/b>: Monday, April 17, 2023
\n
Time<\/b>: 12:00 \u2013 1:30 p.m. Central European Summer Time (CEST)
\n
Session Title<\/b>: 12e. Drug development and treatment modalities (including in vitro<\/i>, animal, clinical trials, resistance)
\n
Poster Number: <\/b>P2633
\n
Title: <\/b>\u201cEDP-235, a Potent, Once-Daily, Oral Antiviral, Demonstrates Potential for Treatment and Prevention of Long COVID\u201d
\n
Presenter<\/b>: <\/i>Yang Li, Ph.D.<\/p>\n

\nDate<\/b>: Monday, April 17, 2023
\n
Time<\/b>: 12:00 \u2013 1:30 p.m. CEST
\n
Session Title<\/b>: 1c. Influenza and respiratory viruses (including diagnostics and epidemiology, antiviral drugs, vaccines, treatment and susceptibility\/resistance)
\n
Poster Number: <\/b>P2844
\n
Title:<\/b> \u201cPharmacokinetics of EDP-323, a Potent, Once-Daily, Oral Antiviral Treatment for Respiratory Syncytial Virus\u201d
\n
Presenter<\/b>: <\/i>Lisha Xu<\/p>\n

\nPosters will be available to view on the conference platform during the conference. Further information about ECCMID 2023 can be found here<\/a>.<\/p>\n

\nAbout Enanta Pharmaceuticals, Inc.
\n
<\/b>Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta\u2019s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).<\/p>\n

\nEnanta\u2019s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). Please visit www.enanta.com<\/a> for more information.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia and Investors<\/b>
Jennifer Viera
\n
617-744-3848
\n
jviera@enanta.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55536","6":"format-standard","7":"category-industry"},"yoast_head":"\nEnanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-05T11:06:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230405005224\/en\/1475183\/21\/Enanta_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)\",\"datePublished\":\"2023-04-05T11:06:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\"},\"wordCount\":381,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005224\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\",\"name\":\"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005224\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"datePublished\":\"2023-04-05T11:06:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005224\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005224\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Pharma Trend","og_description":"WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-05T11:06:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230405005224\/en\/1475183\/21\/Enanta_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","datePublished":"2023-04-05T11:06:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/"},"wordCount":381,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230405005224\/en\/1475183\/21\/Enanta_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/","name":"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230405005224\/en\/1475183\/21\/Enanta_RGB.jpg","datePublished":"2023-04-05T11:06:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230405005224\/en\/1475183\/21\/Enanta_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230405005224\/en\/1475183\/21\/Enanta_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-at-the-33rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55536"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55536\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}